Get all premium features to the best stock analysis tool

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software.

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test.

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1 Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences ABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026.